Hypogammaglobulinemia after front-line immunochemotherapy in patients with follicular lymphoma

被引:1
作者
Acedo, Rocio Diaz [1 ]
Criado, Silvia Artacho [1 ]
Herranz, Eduardo Rios [2 ]
Pizarraya, Antonio Gutierrez [1 ,3 ]
Romero, Irene Sanchez [2 ]
Saavedra, Esther Marquez [1 ]
机构
[1] Univ Hosp Valme, Hosp Pharm Serv, South Seville Hlth Management Area, Seville, Spain
[2] Univ Hosp Valme, Hematol Serv, South Seville Hlth Management Area, Seville, Spain
[3] Hosp Univ Valme, Hosp Pharm Serv, Cra Cadiz S N,Pharm Serv, Seville 41014, Spain
关键词
Hypogammaglobulinemia; follicular lymphoma; chemotherapy; rituximab; PROFOUND HYPOGAMMAGLOBULINEMIA; RITUXIMAB MAINTENANCE; CHEMOTHERAPY; INFECTIONS; THERAPY; RISK;
D O I
10.1177/10781552231162540
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Hypogammaglobulinemia after front-line immunochemotherapy for follicular lymphoma is a poorly studied adverse event that could be related to the appearance of severe and/or recurrent non-neutropenic infections which could affect the quality of life of the patients, even motivating a need of long-term replacement therapy with human immunoglobulins. Methods Observational, retrospective study aiming to estimate the incidence of hypogammaglobulinemia, as well as its severity and clinical consequences, and to explore possible predictive factors for its development. Specific immunoglobulin deficiencies were also studied. Results 76.5% of patients had hypogammaglobulinemia during or after front-line treatment, mostly grade 1-2; with 38.8% patients who developed clinically relevant infections and 20% patients requiring human immunoglobulins replacement therapy. A high-risk FLIPI score was identified as a risk factor for hypogammaglobulinemia (ods ratio: 4.51; 95% confidence interval: 1.29-15.68; p < 0.001) and basal gamma globulin level as a protective factor (odds ratio: 0.92; 95% confidence interval: 0.988-0.996; p = 0.018). Any type of immunochemotherapy regimen was associated with different risks of hypogammaglobulinemia in our study. Conclusions Hypogammaglobulinemia appears in a high percentage of patients with follicular lymphoma in a real-world population, identifying a high-risk FLIPI score as a risk factor for its development and basal gamma globulins as a protective factor.
引用
收藏
页码:1982 / 1989
页数:8
相关论文
共 50 条
[31]   The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany [J].
Hofmann, Sarah ;
Himmler, Sebastian ;
Ostwald, Dennis ;
Duenzinger, Ulrich ;
Launonen, Aino ;
Thuresson, Per-Olof .
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (14) :1017-1026
[32]   Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy [J].
Rodriguez-Sevilla, Juan Jose ;
Fernandez-Rodriguez, Concepcion ;
Bento, Leyre ;
Diez-Feijoo, Ramon ;
Pinzon, Sergio ;
Gibert, Joan ;
Fernandez-Ibarrondo, Lierni ;
Lafuente, Marta ;
Ferrer, Ana ;
Sanchez-Gonzalez, Blanca ;
Gimeno, Eva ;
Sainz, Juan ;
Ramos, Rafael ;
Garcia, Juan F. ;
Colomo, Lluis ;
Bellosillo, Beatriz ;
Gutierrez, Antonio ;
Salar, Antonio .
BLOOD ADVANCES, 2023, 7 (08) :1606-1614
[33]   Follicular lymphoma. High-dose immunochemotherapy with autologous blood stem cell transplantation: Results of the first prospective study in Russia [J].
Nesterova, E. S. ;
Kravchenko, S. K. ;
Mangasarova, Ya. K. ;
Baryakh, E. A. ;
Misyurina, A. E. ;
Vorobyev, V. I. ;
Plastinina, L. V. ;
Chernova, N. G. ;
Kovrigina, A. M. ;
Obukhova, T. N. ;
Klyasova, G. A. ;
Shevelev, A. A. ;
Kostina, I. E. ;
Gemdzhyan, E. G. ;
Gaponova, T. V. ;
Vorobyev, A. I. .
TERAPEVTICHESKII ARKHIV, 2016, 88 (07) :62-71
[34]   A retrospective study on the management of patients with rituximab refractory follicular lymphoma [J].
Solal-Celigny, Philippe ;
Leconte, Pierre ;
Bardet, Aurelie ;
Hernandez, Juana ;
Troussard, Xavier .
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (02) :217-223
[35]   Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403 [J].
Portell, Craig A. ;
Jegede, Opeyemi A. ;
Wagner-Johnston, Nina ;
Nowakowski, Grzegorz S. ;
Fletcher, Christopher ;
Cohen, Jonathon B. ;
Evens, Andrew M. ;
Rosenstein, Lori J. ;
Craig, Jeffrey W. ;
Reddy, Nishitha ;
Kahl, Brad S. .
BLOOD CANCER JOURNAL, 2025, 15 (01)
[36]   Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma [J].
De la Cruz Vicente, Fatima ;
Carrillo-Cruz, Estrella ;
Sole Rodriguez, Maria ;
Marin Niebla, Ana ;
Martino Galiana, Maria Luz ;
Falantes Gonzalez, Jose ;
Montero Cuadrado, Isabel ;
Gonzalez Campos, Jose ;
Espigado Tocino, Ildefonso ;
Rios-Herranz, Eduardo ;
Antonio Perez-Simon, Jose .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (06) :469-475
[37]   Hepatitis C virus-related hepatitis flare after immunochemotherapy in a patient with follicular lymphoma [J].
Motomura, Yotaro ;
Yoshifuji, Kota ;
Tanaka, Keisuke ;
Sakashita, Chizuko ;
Umezawa, Yoshihiro ;
Nagao, Toshikage ;
Nitta, Sayuri ;
Asahina, Yasuhiro ;
Mori, Takehiko ;
Yamamoto, Masahide .
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2024, 64 (04) :313-317
[38]   Bevacizumab as Front-line Treatment of Brain Metastases from Solid Tumors: A Case Series [J].
Zustovich, Fable ;
Ferro, Alessandra ;
Lombardi, Giuseppe ;
Zagonel, Vittorina ;
Fiduccia, Pasquale ;
Farina, Patrizia .
ANTICANCER RESEARCH, 2013, 33 (09) :4061-4065
[39]   Follicular lymphoma: first-line selection criteria of treatment [J].
Nesterova, E. S. ;
Kravchenko, S. K. ;
Kovrigina, A. M. ;
Gemdzhian, E. G. ;
Plastinina, L., V ;
Babaeva, F. E. ;
Obukhova, T. N. ;
Magomedova, A. U. ;
Gaponova, T., V ;
Kremenetskaya, A. M. ;
Vorobyev, A., I .
TERAPEVTICHESKII ARKHIV, 2019, 91 (08) :75-83
[40]   Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience [J].
Bourcier, J. ;
Gastinne, T. ;
Leux, C. ;
Moreau, A. ;
Bossard, C. ;
Mahe, B. ;
Blin, N. ;
Dubruille, V. ;
Touzeau, C. ;
Voldoire, M. ;
Guillaume, T. ;
Peterlin, P. ;
Gallas, P. ;
Garnier, A. ;
Maisonneuve, H. ;
Moreau, P. ;
Juge-Morineau, N. ;
Jardel, H. ;
Chevallier, P. ;
Moreau, P. ;
Le Gouill, S. .
ANNALS OF HEMATOLOGY, 2016, 95 (08) :1287-1293